Developed by Bristol-Myers Squipp, Opdivo (nivolumab) is an FDA approved immunotherapy cancer drug treatment that is showing great promise for treating various types of cancer, including melanoma, lung cancer, kidney cancer and Hodgkin lymphoma. As a disease, cancer escapes the immune system by producing certain proteins that can hide it. As the cancer can cloak itself, the immune system does not detect it. Opdivo is an antibody that binds to the protein called PD-1 on T cells that live in our immune system. T-cells are like a car ignition that gets the immune system off and running, helping it find and kill cancer cells. Visit http://www.oacancer.com/opdivo-immunotherapy-cancer-treatment/ to learn more about this promising new immunotherapy treatment.